NCIC CTG CE.6/TROG 08.02 - GBM in Elderly Patients

By w.paterson
15 August, 2021
0 Comments

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

Primary Sponsor

NCIC Clinical Trials Group (NCIC CTG)

5 December, 2024

Extended follow-up of TROG 99.03 lymphoma trial published

5 December 2024: Study shows huge improvement in progression-free

28 November, 2024

Meet TROG President: A/Prof Puma Sandaresan

28 November 2024: In this Q&A, TROG President A/Prof

Register for the 2025 ASM

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

AGITG/TROG 21.03 – RESOLUTE

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM

NCIC CTG CE.6/TROG 08.02 – GBM in Elderly Patients

A Randomised Phase III study of Temozolomide and short-course radiation versus short-course radiation alone in the treatment of newly diagnosed glioblastoma multiforme in elderly patients.

TROG 04.02 – Cervical – FIGO Stage & Tumour Volume

AGITG/TROG 21.03 – RESOLUTE

Related Post

Extended follow-up of TROG 99.03 lymphoma trial published

Meet TROG President: A/Prof Puma Sandaresan

Register for the 2025 ASM